All
Angiogenesis research provides foundation for drug development
October 1st 2002Paris - Increased understanding of the basic molecular mechanisms involved in angiogenesis has suggested new targets for treating a number of dermatological and other diseases, and many compounds affecting angiogenesis are in clinical trials. However, questions remain to be answered about potential strategies for optimizing the efficacy of pro- and anti-angiogenic interventions and the safety of these novel treatments, Peter Carmeliet, Ph.D., said at the World Congress of Dermatology.
Tazarotene indications may soon expand
October 1st 2002Los Angeles - Already approved for the treatment of acne, tazarotene (Tazorac) is being investigated for the treatment of facial photodamage and clogged pores. The FDA is expected to grant regulatory approval for tazarotene to treat photodamaged facial skin within a few months.
Some hope remains this year for Medicare bill
October 1st 2002There is still hope for a Medicare "giveback" bill before Congress adjourns for good this year, and the possibility of a broader Medicare drug benefit than the discount card just announced by the Bush administration could be the best last chance to get this done.
Long-term tretinoin use improves cellular atypia
October 1st 2002Los Angeles - Dermatologists concerned that long-term topical tretinoin use might worsen epidermal cellular atypia can rest assured it does not, according to a study presented at the annual meeting of the Society for Investigational Dermatology. In fact, the treatment used commonly to rid patients of the fine lines and mottled discoloration of sun damage improves epidermal cellular atypia.
Stem cells may aid in postischemic revascularization
September 15th 2002Los Angeles - The restoration of the blood flow in ischemic limbs in mice is accelerated when epidermal stem cells are injected into the site, Martine Dunnwald, PharmD, Ph.D., told colleagues at the annual meeting of the Society for Investigative Dermatology.
IgM antibodies occur earlier than IgG in EM
September 1st 2002Los Angeles -The kinetics of Borrelia burgdorferi antibody titers in 394 patients with erythema migrans and correlations of IgM and IgG antibody profiles with clinical disease were described at the annual meeting of the Society for Investigative Dermatology.
New technology, patient demand spur cosmetic surgery advances
September 1st 2002New Orleans - Significant technological developments continue to advance laser and cosmetic surgery, according to Jeffrey Dover, M.D., who reviewed progress in the field over the last year at the annual meeting of the American Academy of Dermatology here.
Spin trap-like compounds may block inflammation, deter aging
September 1st 2002Chicago - Several bioactive compounds similar to spin traps have been identified that can cool down and block the process of inflammation and also stop the molecular events involved in the aging of skin, Bryan Fuller, Ph.D., said. A particular compound, called Quadrinone, has now been formulated into a topical therapeutic product for problem skin.
Cosmetic practice poses ethical challenges
September 1st 2002New Orleans - Cosmetic dermatology presents a number of complex ethical issues for clinicians and researchers alike, but the bottom line for measuring what constitutes ethical practice is to consider whether patients are being treated as the physician would care for himself or his own family, Andrew C. Markey, M.D., said at the annual meeting of the American Academy of Dermatology.
Fibroblasts found to have surprising proliferative potential into old age
September 1st 2002San Antonio - One take-home lesson from a study on aging is that even the fibroblasts of very old people have significant proliferative potential, James R. Smith, Ph.D., said. "This suggests that fibroblasts may not be the best cells to use in determining a relationship between in vivo and in vitro aging," he said.
Extracted autologous veins fill facial soft-tissue defects
September 1st 2002New Orleans - Autologous veins extracted during ambulatory phlebectomy procedures provide a safe and effective material for facial soft tissue augmentation and correction of atrophic dermal defects, Mitchel P. Goldman, M.D., said at the annual meeting of the American Academy of Dermatology.
Deep excision necessary for merkel cell carcinoma
September 1st 2002New Orleans - Merkel cell carcinoma is a very rare tumor - U.S. physicians see only about 500 cases a year. It is also a surprisingly deep-seated skin lesion, and therefore extra attention should be paid to excision, Mary Maloney, M.D., said during her presentation on Mohs surgery at the annual meeting of the American Academy of Dermatology.
Poll garners patient, prescriber opinions on AK treatments
September 1st 2002New Orleans - Patients and physicians express various levels of satisfaction and dissatisfaction with the most common treatment modalities for actinic keratoses. Both groups have strong interest as well in newer therapies, according to the results of a survey presented by James Q. Del Rosso, D.O., at the annual meeting of the American Academy of Dermatology.
Varicella vaccine could be effective zoster prophylactic for older patients
September 1st 2002Stanford, Calif. - Use of an inactivated varicella vaccine may prevent immunocompromised patients from developing varicella-zoster virus infection for up to a year, Ann Arvin, M.D., said. She and colleagues published a recent study in the New England Journal of Medicine showing up to 20 percent fewer patients who were varicella seropositive developed zoster a year after a hematopoietic cell transplant.
Estrogen's keratinocyte connection
September 1st 2002Los Angeles -- In an attempt to prove estrogen's unknown effect on keratinocytes, researchers presented in vitro data at the Society for Investigative Dermatology that suggest a direct link of the hormone to in vivo epidermal turnover and wound healing.
Women First HealthCare acquires Vaniqa, plans relaunch
September 1st 2002San Diego - With its acquisition from Bristol-Myers Squibb of worldwide rights and title to Vaniqa (eflornithine hydrochloride) Cream, Women First HealthCare plans to take another pass at providing women with hirsutism a pharmaceutical alternative.
Mast cells play key role in bacterial infection defense
September 1st 2002Los Angeles -- Mast cells are directly involved in innate defense against bacterial infection through the synthesis of antimicrobial peptides, according to research presented at the annual meeting of the Society for Investigative dermatology.
Tobacco isolated as cause of skin aging
September 1st 2002Los Angeles - Researchers in The Netherlands who looked at nearly 1,000 patients added to the confirmation that smoking causes wrinkles and enhances skin aging in both sexes. They also found that smoking seems to wreak even more havoc on men's skin, causing telangiectasias. So, they said, smoking may have different effect on men and women when it comes to skin changes.
Rosacea extra-facial signs common
September 1st 2002Los Angeles -- Researchers conducting a study to determine the frequency of extra-facial lesions of the erythemotelangiectatic or papulopustular subtypes in rosacea patients found that erythema on the trunk and telangiectasia on the neck were associated with the erythemotelangiectatic subtype.
Are derm surgeons properly trained?
September 1st 2002New Orleans - The training received by dermatologic surgeons is more than adequate for the task; in fact, dermatologists pioneered many of the skin surgery techniques in common use today, outgoing American Academy of Dermatology president Ronald G. Wheeland, M.D., said here at a "controversies in dermatology" session at the AAD's annual meeting
Office efficiency can be found in little changes
September 1st 2002New Orleans - Working smarter, not harder, is a rule people want to live by but is often more difficult than it sounds. In a medical practice setting, where efficiency can sometimes fall by the wayside, physicians must keep an eye out for simple but smart strategies to overcome office shortcomings.
Fluconazole Tx for cutaneous leishmaniasis
September 1st 2002Riyadh, Saudi Arabia - For treatment of cutaneous leishmaniasis caused by Leishmania major, a six-week course of oral fluconazole is effective and avoids the potentially severe side effects of standard parenteral therapy, according to Abdulrahman A. Alrajhi, M.D., M.P.H.